Biotechnology - Financial

Filter

Current filters:

Financial

Popular Filters

1 to 25 of 437 results

Gilead third-qtr sales beat expectations, but Sovaldi disappoints

Gilead third-qtr sales beat expectations, but Sovaldi disappoints

29-10-2014

There was mixed news late yesterday from US anti-virals major Gilead Sciences, when the biotech posted…

Anti-viralsBiotechnologyFinancialGilead SciencesHarvoniSovaldiUSA

Ferrer buys $8 million of Alexza shares, to eliminate certain Adasuve milestone payments

Ferrer buys $8 million of Alexza shares, to eliminate certain Adasuve milestone payments

28-10-2014

US drugmaker Alexza Pharmaceuticals and privately-held Spanish firm Grupo Ferrer Internacional have amended…

AdasuveAlexza PharmaceuticalBiotechnologyFerrer InternacionalFinancialLicensingNeurologicalUSA

Licensing deal index shows re-emergence of late-stage deals

Licensing deal index shows re-emergence of late-stage deals

28-10-2014

Licensing deals among biotech companies have recently shown a healthy surge, especially in later stages.

BiotechnologyCelgene Corp.FinancialLicensingMorrisonUK

Despite restructuring costs, Amgen’s third-qtr beats expectations

Despite restructuring costs, Amgen’s third-qtr beats expectations

28-10-2014

US biotech major Amgen posted a fall in earnings for the third-quarter of 2014, due to restructuring,…

AmgenBiotechnologyFinancialThousand Oaks, CaliforniaUSA

Celgene third-quarter results beat estimates; ups guidance

Celgene third-quarter results beat estimates; ups guidance

23-10-2014

US biotech major Celgene today reported better-than-expected financial results, with net product sales…

BiotechnologyCelgene Corp.Celgene Corp.FinancialUnited StatesUSA

Biogen Idec third-qtr net rockets 76% but shares slump

Biogen Idec third-qtr net rockets 76% but shares slump

23-10-2014

US biotech firm Biogen Idec saw its share price plunge 7% to $303.51, after its posted third-quarter…

Biogen IdecBiotechnologyFinancialNeurologicalTecfideraUSA

Amgen advised to consider ‘radical’ split by lead investor

Amgen advised to consider ‘radical’ split by lead investor

22-10-2014

One of Amgen’s largest shareholders has said the USA-based biotechnolgy comapny would be better off…

AmgenBiotechnologyFinancialThousand Oaks, CaliforniaUK

Actelion beats expectations as third-qtr net profit rockets 39%

Actelion beats expectations as third-qtr net profit rockets 39%

21-10-2014

Switzerland’s Actelion, Europe’s largest biotech company, this morning announced third-quarter 2014…

ActelionBiotechnologyFinancialOpsumitRespiratory and PulmonarySwitzerlandTracleer

Profectus BioSciences gets US government funding for Ebola vaccine development

17-10-2014

Under a one-year contract with US biotech firm Profectus BioSciences, the US Department of Health and…

Anti-viralsBiotechnologyFinancialProfectus BioSciencesResearchUSA

Biotherapies could save millions of euros when treating auto-immune diseases

Biotherapies could save millions of euros when treating auto-immune diseases

08-10-2014

Health care providers could save millions of euros if biotherapies were used in the treatment of Crohn’s…

Anti-Arthritics/RheumaticsBiotechnologyEuropeFinancialHealthcareResearchTheradiag

Incyte earns $60 million milestone on European reimbursement for Jakavi

Incyte earns $60 million milestone on European reimbursement for Jakavi

02-10-2014

US biopharma company Incyte says that it has earned a $60 million milestone payment from Swiss pharma…

BiotechnologyEuropeFinancialIncyteJakafiJakaviNovartisOncologyPricing

Denmark’s Forward Pharma plans IPO

Denmark’s Forward Pharma plans IPO

02-10-2014

Denmark-based Forward Pharma A/S today announced it has commenced an underwritten initial public offering…

BiotechnologyDenmarkFinancialForward PharmaImmunologicals

Adaptimmune completes $104 million round of financing to advance cancer therapies

Adaptimmune completes $104 million round of financing to advance cancer therapies

25-09-2014

Adaptimmune, a UK biotech company focused on using T-cell therapy to treat cancer and infectious disease,…

AdaptimmuneBiotechnologyFinancialGlaxoSmithKlineOncologyUK

Nanobiotix expands into USA with office in Boston life sciences cluster

Nanobiotix expands into USA with office in Boston life sciences cluster

22-09-2014

France-based Nanobiotix, a clinical-stage nanomedicine company pioneering novel approaches for the local…

BiotechnologyFinancialFranceNanobiotixOncologySanofiUSA

Australian government announces funding available for Soliris

18-09-2014

The Pharmaceutical Benefits Advisory Committee (PBAC) has recommended to the Australian government that…

Alexion PharmaceuticalsAustraliaBiotechnologyFinancialPricingRare diseasesSoliris

Celgene cancer drug approved for PBS listing in Australia

17-09-2014

Pancreatic cancer drug Abraxane (paclitaxel protein-bound particles for injectable suspension), from…

AbraxaneAustraliaBiotechnologyCelgene Corp.FinancialOncologyPricing

SIGA Technologies files for Chapter 11 reorganization

SIGA Technologies files for Chapter 11 reorganization

16-09-2014

Biological warfare defense firm SIGA Technologies has filed a voluntary petition for relief under chapter…

Anti-viralsBiotechnologyFinancialLegalPharmAtheneSIGA TechnologiesTecovirimatUSA

India’s Dept of Biotech plans financial help for the biotech industry

India’s Dept of Biotech plans financial help for the biotech industry

15-09-2014

Anti-cancer compounds, immunogens against H1N1, cheap recombinant human insulin, stem cell research -…

BiotechnologyFinancialIndiaResearch

Action urged to capitalize on opportunity as Australian budget tables reveal loss of support

04-09-2014

The release of the Australian federal government’s ‘Science, Research and Innovation Budget Tables’…

AustraliaBiotechnologyFinancialResearch

US HHS contracts with Mapp Biopharmaceutical to develop Ebola drug

03-09-2014

The US Department of Health and Human Services has awarded a $25 million contract to Mapp Biopharmaceutical…

Anti-viralsBiotechnologyFinancialMapp BiopharmaceuticalResearchTropical diseasesUSAZMapp

Australian medical bodies advocate for the government's Medical Research Future Fund

Australian medical bodies advocate for the government's Medical Research Future Fund

02-09-2014

Australian medical bodies are collaborating to advocate for the Medical Research Future Fund (MRFF) proposed…

AustraliaBiotechnologyFinancialMRFF Action GroupPolitics

AusBiotech welcomes Greens' push for quarterly payments on R&D Tax Incentive

AusBiotech welcomes Greens' push for quarterly payments on R&D Tax Incentive

28-08-2014

Trade group AusBiotech says it fully supports the Australian Greens’ moving of an amendment in the…

AustraliaBiotechnologyFinancialResearch

ViaCyte gets $20 million in deal with Janssen

ViaCyte gets $20 million in deal with Janssen

22-08-2014

Privately held US regenerative medicine company ViaCyte has entered into a rights agreement with Janssen…

BiotechnologyDiabetesEndocrine systemFinancialJanssenJohnson & JohnsonLicensingUSAVC-01ViaCyte

1 to 25 of 437 results

Parexel

Parexel

Back to top